Humacyte, Inc.

NASDAQ:HUMA

Biotechnology

Healthcare
$0.50 -3.35%

-$0.03 today

Market cap
$139.18M
Beta
2.46
P/E (TTM)
-1.9
EPS (TTM)
-$0.49
52W Low $0.55High $2.84

Volume 4.34M

Average 8.14M

Returns on capital

Humacyte, Inc. management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

-1313.4%

avg -291.4%

ROIC

-107.0%

avg -68.8%

ROA

-35.1%

avg -51.1%

Analysis

ROA is currently the strongest return metric at -35.1% versus its period average of -51.1%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Laura E. Niklason

Founder, President, Chief Executive Officer & DirectorUSD 902.18K6380.00K0.05%

Dale A. Sander

Chief Financial Officer, Chief Corporate Development Officer & TreasurerUSD 735.5K66267.21K0.16%

Shamik J. Parikh

Chief Medical OfficerUSD 700.4K53272.71K0.16%

Heather Connelly

Chief Quality & Regulatory Officer————

Todd E. Rasmussen

Chief Surgical Officer————

Jim Mercadante

Chief Commercial Officer————

Rick McElheny

Senior Vice President of Business Development————

Lisa Molyneux

Chief Strategy Officer————

Sabrina Osborne

Chief People Officer————

Compensation is shown in the reported currency; data updated Nov 7, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Jun 11, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

Buys

5

$90,209.34

Sells

2

$82,293.75

Net Transaction Value

+$7,915.59

Net buying

Most Active

Jones Keith Anthony

3 transactions

Transactions sorted by date, descending.

Open-market insider purchases and sales reported during the last 12 months
Type
Sep 14, 26

Jones Keith Anthony

Direct

Buy$5.6K
Aug 20, 26

Jones Keith Anthony

Direct

Buy$6.9K
Aug 17, 26

Jones Keith Anthony

Direct

Buy$17.8K
May 19, 26

Sebelius Kathleen

Direct

Buy$50K
May 18, 26

Constantino Michael T.

Direct

Buy$9.8K
May 18, 26

Sander Dale A.

Direct

Sell$41.1K
May 18, 26

Parikh Shamik J

Direct

Sell$41.1K

Summary

Insiders reported 5 buys worth $90,209.34 and 2 sells worth $82,293.75 over the last 12 months. That adds up to net buying of $7,915.59. Jones Keith Anthony was the most active insider with 3 transactions.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A1 analysts
RevenueN/AN/A+9.2%
+176.2% (5yr)2 analysts
Net IncomeN/AN/AN/A
N/A2 analysts
EBITN/AN/AN/A
N/A2 analysts

Analysis

Recent growth has been strongest in Revenue at +9.2% over three years. Forward estimates point to Revenue at +176.2% (5yr), giving you a quick check on whether expectations are accelerating or cooling.

Competitors

Who does Humacyte, Inc. compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about HUMA's management, answered from reported figures.

Who manages HUMA?

Humacyte, Inc. (HUMA) lists 9 active executives. The top listed executive is Heather Connelly, Chief Quality & Regulatory Officer.

Are HUMA insiders buying or selling?

Recent insider activity shows net selling of $123.31M.